Skip to main content
Signal8
DEBBANE RAYMOND profile photo

Raymond Debbane

CIK: 0001053890

Transaction Breakdown

Open Market Buys (P)7 (53.8%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)2 (15.4%)

Derivative conversions

Awards (A)4 (30.8%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

LEXICON PHARMACEUTICALS, INC. logo
LXRX

LEXICON PHARMACEUTICALS, INC.

Director

Discretionary Trading P&L

Holdings

Transaction History (13 total)

  • LEXICON PHARMACEUTICALS, INC. logo
    LXRX

    LEXICON PHARMACEUTICALS, INC.

    Jun 3, 2026
    Exercise(M)
    Direct
    89.3K shares-
  • LEXICON PHARMACEUTICALS, INC. logo
    LXRX

    LEXICON PHARMACEUTICALS, INC.

    May 1, 2026
    Award(A)

    Restricted Stock Units

    Direct
    35.7K shares-
  • LEXICON PHARMACEUTICALS, INC. logo
    LXRX

    LEXICON PHARMACEUTICALS, INC.

    May 1, 2026
    Award(A)

    Stock Option (Right to Buy)

    Direct
    43.5K shares-
  • LEXICON PHARMACEUTICALS, INC. logo
    LXRX

    LEXICON PHARMACEUTICALS, INC.

    Feb 25, 2026
    Purchase(P)
    Direct
    2K shares at avg. $1.49$3K
  • LEXICON PHARMACEUTICALS, INC. logo
    LXRX

    LEXICON PHARMACEUTICALS, INC.

    Feb 23, 2026
    Purchase(P)
    Direct
    100K shares at avg. $1.47$147K
  • LEXICON PHARMACEUTICALS, INC. logo
    LXRX

    LEXICON PHARMACEUTICALS, INC.

    Feb 20, 2026
    Purchase(P)
    Direct
    100K shares at avg. $1.48$148K
  • LEXICON PHARMACEUTICALS, INC. logo
    LXRX

    LEXICON PHARMACEUTICALS, INC.

    Feb 19, 2026
    Purchase(P)
    Direct
    50K shares at avg. $1.44$72K
  • LEXICON PHARMACEUTICALS, INC. logo
    LXRX

    LEXICON PHARMACEUTICALS, INC.

    Feb 18, 2026
    Purchase(P)
    Direct
    133.7K shares at avg. $1.32$176K
  • LEXICON PHARMACEUTICALS, INC. logo
    LXRX

    LEXICON PHARMACEUTICALS, INC.

    Feb 17, 2026
    Purchase(P)
    Direct
    76.9K shares at avg. $1.31$101K
  • LEXICON PHARMACEUTICALS, INC. logo
    LXRX

    LEXICON PHARMACEUTICALS, INC.

    Feb 13, 2026
    Purchase(P)
    Direct
    58K shares at avg. $1.31$76K
  • LEXICON PHARMACEUTICALS, INC. logo
    LXRX

    LEXICON PHARMACEUTICALS, INC.

    Jun 3, 2025
    Award(A)

    Stock Option (Right to Buy)

    Direct
    103.8K shares-
  • LEXICON PHARMACEUTICALS, INC. logo
    LXRX

    LEXICON PHARMACEUTICALS, INC.

    Jun 3, 2025
    Award(A)

    Restricted Stock Units

    Direct
    89.3K shares-
  • LEXICON PHARMACEUTICALS, INC. logo
    LXRX

    LEXICON PHARMACEUTICALS, INC.

    May 13, 2025
    Exercise(M)
    Direct
    36.8K shares-

1-13 of 13

About DEBBANE RAYMOND

DEBBANE RAYMOND (SEC CIK 0001053890) files insider reports with the SEC as Director of LEXICON PHARMACEUTICALS, INC. (LXRX).

Signal8 holds 8 ownership filings by DEBBANE RAYMOND, all Form 4s, filed between May 13, 2025 and Jun 4, 2026. Those filings report 13 transactions, from May 13, 2025 to Jun 3, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on DEBBANE RAYMOND's filings is in THE WOODLANDS, TX.

Recent filings by DEBBANE RAYMOND

  • Jun 3, 2026: Option exercise of LXRX shares (Form 4, code M).
  • May 1, 2026: Grants or awards of LXRX derivative securities (2 lines, Form 4, code A).
  • Feb 25, 2026: Open-market purchase of LXRX shares (Form 4, code P).
  • Feb 23, 2026: Open-market purchase of LXRX shares (Form 4, code P).
  • Feb 20, 2026: Open-market purchase of LXRX shares (Form 4, code P).

Other insiders filing for LEXICON PHARMACEUTICALS, INC. (LXRX)

How to read Form 4 transaction codes